In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
14 authors at 8 institutions in 1 country.
Natalie R DavidsonDepartment of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-1745-8072 Mollie E BarnardHuntsman Cancer Institute and the Department of Population Health Sciences at the Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-4843-4655 Ariel A HippenDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9336-6543 Amy CampbellDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Courtney E JohnsonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Gregory P WayDepartment of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-0503-9348 Brian K DalleyHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University, Durham, NC.
Lucas A SalasDepartment of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-2279-4097 Lauren C PeresDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-6620-8600 Jeffrey R MarksDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Joellen M SchildkrautDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Casey S GreeneDepartment of Biomedical Informatics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-8713-9213 Jennifer A DohertyHuntsman Cancer Institute and the Department of Population Health Sciences at the Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.
Translational Therapeutics (United States) · USDartmouth College · USDuke University · USEmory University · USBoston University · USMoffitt Cancer Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Utah · US
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MEpidemiology of Ovarian Cancer in African-American WomenR01CA142081 · NCI · UNIVERSITY OF VIRGINIA · PI SCHILDKRAUT, JOELLEN M. · 2010 to 2015
$10.6MThe Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2MCharacterization of high-grade serous ovarian cancer subtypes via single-cell profilingR01CA237170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI DOHERTY, JENNIFER A., GREENE, CASEY S · 2019 to 2024
$3.0MCharacterizing Molecular Subtypes of Ovarian Cancer in African-American WomenR01CA200854 · NCI · UNIVERSITY OF UTAH · PI DOHERTY, JENNIFER A., SCHILDKRAUT, JOELLEN M. · 2016 to 2021
$2.8MThe Role of Inflammation in the Racial Disparities in Ovarian Cancer SurvivalR00CA218681 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PERES, LAUREN COLE · 2018 to 2020
$722kInflammation and gynecologic cancer: the role of prostaglandins in ovarian cancerK00CA212222 · NCI · UNIVERSITY OF UTAH · PI BARNARD, MOLLIE ELYSE · 2018 to 2021
$415kNCI NIH HHS K00 CA212222NCI NIH HHS P30 CA042014NCI NIH HHS R00 CA218681NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA142081NCI NIH HHS R01 CA200854NCI NIH HHS R01 CA237170
6 · The paper itselfAbstract
Introduction: High-grade serous carcinoma (HGSC) gene expression subtypes are associated with differential survival. We characterized HGSC gene expression in Black individuals and considered whether gene expression differences by race may contribute to poorer HGSC survival among Black versus non-Hispanic White individuals. Methods: We included newly generated RNA-Seq data from Black and White individuals, and array-based genotyping data from four existing studies of White and Japanese individuals. We assigned subtypes using K-means clustering. Cluster- and dataset-specific gene expression patterns were summarized by moderated t-scores. We compared cluster-specific gene expression patterns across datasets by calculating the correlation between the summarized vectors of moderated t-scores. Following mapping to The Cancer Genome Atlas (TCGA)-derived HGSC subtypes, we used Cox proportional hazards models to estimate subtype-specific survival by dataset. Results: Cluster-specific gene expression was similar across gene expression platforms. Comparing the Black study population to the White and Japanese study populations, the immunoreactive subtype was more common (39% versus 23%-28%) and the differentiated subtype less common (7% versus 22%-31%). Patterns of subtype-specific survival were similar between the Black and White populations with RNA-Seq data; compared to mesenchymal cases, the risk of death was similar for proliferative and differentiated cases and suggestively lower for immunoreactive cases (Black population HR=0.79 [0.55, 1.13], White population HR=0.86 [0.62, 1.19]). Conclusions: A single, platform-agnostic pipeline can be used to assign HGSC gene expression subtypes. While the observed prevalence of HGSC subtypes varied by race, subtype-specific survival was similar.
Identifiers
PMID37961178
PMCPMC10635053
OpenAlexW4388384094
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390